Shed vs Willow: Name-brand, Compounded, and Coaching
Shed vs Willow is a straightforward choice between two telehealth weight management approaches: Shed pairs name-brand and compounded GLP-1 options with continuous coaching and a 2-minute approval assessment, while Willow focuses on an oral GLP-1 program with progress tracking and follow-up support. Early verdict: choose Shed if you want both name-brand and compounded medication options plus bundled coaching; choose Willow if you want a telehealth program built around oral GLP-1 and structured follow-up.
Explore Shed’s medication and coaching
How they differ at a glance
This direct comparison highlights the most distinctive supported differences: medication types offered, coaching and follow-up model, program structure and workflow, pricing signals, and regulatory notes about compounded products. All statements below reflect only the supplied source material.
| Criteria | Shed | Willow |
|---|---|---|
| Primary treatment format | Name-brand and compounded GLP-1 injections and options | Oral GLP-1 program with progress tracking |
| Coaching or follow-up | Continuous coaching integrated into treatment | Follow-up consultations and progress tracking tools |
| Approval workflow | 2-minute online approval assessment, clinician review | Telehealth-first workflow with licensed team; clinician determines appropriateness |
| Starting price mentioned | Compounded semaglutide starting at $199/month; tirzepatide starting at $299/month | Starting price listed as $299 on captured page |
| Promotions | 10% off your first month for new patients | No readable promotional evidence captured |
| Regulatory note | Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality | Medication-specific approval status must be confirmed; branded and compounded products are not interchangeable |
Medication options and regulatory context
Shed explicitly offers both FDA-approved name-brand GLP-1 medications and compounded alternatives, giving patients a choice based on budget and preference. The source emphasizes that compounded medications are not FDA-approved and are prepared by a licensed pharmacy based on a provider’s prescription. Willow is presented as an oral GLP-1 program; the captured evidence notes that medication-specific approval status must be confirmed and warns that branded and compounded products are not interchangeable. If the approval status of a specific product matters to you, the supplied material does not provide additional verification beyond these qualifiers.
Check Shed’s name-brand and compounded options
Coaching, tracking, and ongoing support compared
Shed markets continuous coaching integrated into treatment rather than issuing a prescription only. The source describes coaching that supports titration, lifestyle changes, and plateaus. Willow emphasizes progress tracking tools and follow-up consultations, framing its oral GLP-1 offering as a structured weight management journey with digital follow-up to convert medication benefit into longer term outcomes. Both providers require a licensed clinician to determine medical appropriateness before treatment is issued.
Pricing signals and workflow
The captured Shed evidence lists compounded semaglutide injections starting at $199/month and compounded tirzepatide starting at $299/month, plus a limited time 10% off first month offer. Shed also states that standard pricing is not published and that patients receive a personalized quote after intake. Willow’s captured page included a starting price of $299 but the landing page evidence was not readable. The source for Willow notes a simple digital workflow and licensed telehealth team. The detailed terms, shipping, membership, or cancellation policies for Willow were not verified on the captured page.
See Willow’s oral GLP-1 program
Which differences matter most
1) Medication variety: Shed is notable for offering both name-brand and compounded GLP-1; Willow centers on oral GLP-1. 2) Support model: Shed integrates continuous coaching; Willow emphasizes progress tracking and follow-up consultations. 3) Pricing transparency: Shed lists starting prices for compounded injections and a 10% first-month offer but does not publish standard pricing; Willow shows a starting price capture of $299 without readable supporting detail. 4) Regulatory cautions: The supplied material preserves that compounded medications are not FDA-approved, and Willow’s capture advises confirming medication-specific approval status.
Quick recap
In this Shed vs Willow comparison, Shed is characterized by mixed medication options plus bundled coaching and a fast 2-minute assessment, while Willow is characterized by an oral GLP-1 program with structured tracking and follow-up support. Results and suitability depend on clinician review and the specific products chosen.
Compare Willow follow-up and tracking
Choose one if…
Choose Shed if you want the option to select between FDA-approved name-brand GLP-1 and compounded alternatives, value continuous coaching integrated into treatment, and are interested in a 2-minute approval assessment plus a 10% off first month offer. Choose Willow if you prefer a telehealth-first oral GLP-1 program built around progress tracking and structured follow-up consultations.
All treatment is available only when a licensed clinician determines it is medically appropriate. Compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality. Additional details such as full pricing, shipping, membership, and cancellation terms were not fully captured for Willow in the supplied material.